中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值早期动态变化对免疫检查点抑制剂治疗头颈部鳞状细胞癌疗效的预测价值。

Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma.

机构信息

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.

出版信息

Oral Surg Oral Med Oral Pathol Oral Radiol. 2024 Dec;138(6):763-771. doi: 10.1016/j.oooo.2024.07.014. Epub 2024 Aug 10.

DOI:10.1016/j.oooo.2024.07.014

PMID:39181857

Abstract

OBJECTIVE

We analyzed the predictive value of dynamic changes in neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors (ICIs).

STUDY DESIGN

A total of 104 patients with R/M HNSCC treated with ICIs during August 2018 to June 2023 were included. Dynamic changes were defined as the difference between NLR and PLR on day 1 of cycles 1 and 2.

RESULTS

Patients with increased NLR or PLR had an independently increased risk of disease progression at the first response evaluation (odds ratio [OR] 5.26, P = .005; OR 2.29, P = .042), disease progression (hazard ratio [HR] 2.29, P = .003; HR 1.68, P = .027), and death (HR 1.86, P = .027; HR 1.68, P = .037). Furthermore, patients with a decrease in NLR showed longer progression-free survival, with HRs of 0.36 (P < .001) for those with low pre-ICI NLR and 0.52 (P = .041) for those with high pre-ICI NLR, compared to those with increased NLR.

CONCLUSIONS

Increased NLR or PLR was associated with adverse outcomes after ICI treatment in patients with R/M HNSCC.

摘要

目的

我们分析了中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）在接受免疫检查点抑制剂（ICI）治疗的复发性和/或转移性（R/M）头颈部鳞状细胞癌（HNSCC）患者中的预测价值。

研究设计

共纳入 104 例在 2018 年 8 月至 2023 年 6 月期间接受 ICI 治疗的 R/M HNSCC 患者。动态变化定义为第 1 周期和第 2 周期第 1 天 NLR 和 PLR 的差值。

结果

NLR 或 PLR 升高的患者在首次反应评估时疾病进展的风险独立增加（优势比 [OR] 5.26，P =.005；OR 2.29，P =.042）、疾病进展（风险比 [HR] 2.29，P =.003；HR 1.68，P =.027）和死亡（HR 1.86，P =.027；HR 1.68，P =.037）。此外，NLR 降低的患者具有更长的无进展生存期，低基线 NLR 的患者 HR 为 0.36（P <.001），高基线 NLR 的患者 HR 为 0.52（P =.041），与 NLR 升高的患者相比。